RESEARCH ARTICLE

[View Article Online](#)
[View Journal](#) | [View Issue](#)

Cite this: *Med. Chem. Commun.*,
2017, 8, 2173

Thiosemicarbazone-based selective proliferation inactivators inhibit gastric cancer cell growth, invasion, and migration†

Biao Hu,‡ Bo Wang,‡ Bing Zhao,‡ Qian Guo, Zhong-Hua Li, Xin-Hui Zhang, Guang-Yao Liu, Ying Liu, Ying Tang, Fan Luo, Ya Du, Ya-Xin Chen, Li-Ying Ma * and Hong-Min Liu*

A series of novel thiosemicarbazone derivatives were synthesized and evaluated for their antiproliferative activity against several selected tumor cell lines of different origins using the MTT assay. The preliminary results indicated that the MGC-803 cell line was remarkably sensitive to all the synthesized compounds. Among this series, compound **5n** showed the best inhibitory activity with an IC₅₀ value of 0.93 μM (about 10-fold more potent than **3-AP**) against MGC-803. Further mechanism studies revealed that compound **5n** could obviously inhibit the proliferation of MGC-803 cells by inducing apoptosis and arresting the cell cycle at the S phase. Compound **5n** also showed marked inhibition of cell migration and invasion, without significant cytotoxicity against gastric epithelial immortalized GES-1 cells.

Received 14th July 2017,
Accepted 19th September 2017

DOI: 10.1039/c7md00353f

rsc.li/medchemcomm

Introduction

Cancer, being one of the leading causes of death globally, poses a major socioeconomic hazard to humanity at large. Although there has been progress in the development of prevention and treatment of cancer, successful treatment of cancer remains a challenge. There is still an urgent need to search for some newer and safer anticancer agents that have a broader spectrum of cytotoxicity to cancer cells.

As reported, neoplastic cells have high requirements for metal due to their generally higher rates of proliferation than normal cells. Considering the crucial roles of these metals, development of novel metal chelators has become a promising anticancer strategy.¹ Many *in vitro* and *in vivo* studies and clinical trials have demonstrated that metal (Fe, Cu, and Zn) chelators are effective antiproliferative agents.²

Multi-functionalized thiosemicarbazones and their metal complexes have been a focus of chemists and biologists because of their wide range of therapeutic uses with antiviral, antiparasitic, antibacterial, anticonvulsant, and, most intriguingly, anticancer activity.^{3–14} Encouraged by the modest results obtained with traditional metal chelators, a variety of

novel thiosemicarbazone-based ligands with antiproliferative activity have been identified (Fig. 1), including **3-AP**,¹⁵ **Dp44mT**,^{16,17} **Ap44mT**,^{18–21} and **DpC**.^{22–24} In fact, **3-AP** has been investigated in over 20 phase I and phase II clinical trials in a variety of advanced cancers.^{25–27} Unfortunately, **3-AP** has suffered multiple problems, including low efficacy in some tumor-types and serious side effects, which limit its clinical utility.^{28–30} Therefore, highly selective chelators with strong toxicity toward cancer cells and less or no side effects on normal cells remain to be identified.

A key feature of progressive tumors is having the potential to invade neighboring tissue and to spread throughout the body and form metastatic lesions at distant sites.³¹ In addition, there is increasing evidence that epithelial-mesenchymal transition (EMT) is a key step for cancer cell migration, invasion, and metastasis.³² During the process of EMT, cells lose their epithelial characteristics such as epithelial morphology, cell polarity, and cell-cell contact, and gain mesenchymal properties such as fibroblastic morphology and increased migration and invasion, causing cancer cell metastasis.^{33–36}

We have previously reported a novel series of pyrimidine-based hybrids with potent anticancer activity. One of the compounds, **6-LM** (Fig. 1), a thiosemicarbazone-containing pyrimidine hybrid, showed marked inhibition of cell migration and invasion *in vitro* and *in vivo*.³⁷ To explore the mechanism of compound **6-LM** regulated EMT more thoroughly, we designed a series of small molecules and evaluated their antitumor activity using thiosemicarbazone as a minimal scaffold.

Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key Laboratory of Technology of Drug Preparation, Ministry of Education of China, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, PR China. E-mail: yingdejiqing1314@163.com, liuhm@zzu.edu.cn

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7md00353f

‡ These authors contributed equally to this work.

Fig. 1 Representative examples of thiosemicarbazone derivatives.

Results and discussion

Chemistry

The general route for the synthesis of the target thiosemicarbazones is depicted in Scheme 1. Commercially available **1a–c** were reacted with CS₂ and hydrazine hydrate in the presence of triethylamine to form compounds **4a–c**, which were subjected to reaction with an appropriately substituted aldehyde to afford the target compounds **5a–q** with good yields.

Evaluation of biological activity

Anti-proliferative activity. All the compounds synthesized in this study were examined for their anti-proliferative activity against three human cancer cell lines (commercially available from Cell Bank, Shanghai Institutes for Biological Sciences, Shanghai, China) such as MGC-803 (human gastric cancer cell line), SMMC-7721 (human liver cancer cell line), and MCF-7 (human breast cancer cell line). **3-AP** was chosen as a positive control. The results of preliminary evaluation are summarized in Table 1.

During the SAR studies, we found that all synthesized compounds showed a more potent inhibitory activity against MGC-803 than SMMC-7721 and MCF-7. This observation suggests that these compounds may act through targeting specific biological targets that are overexpressed in certain cells. In addition, a slight difference in inhibition of growth of MGC-803 cells was observed for compounds with different substitution patterns. A significant boost in potency came

from the substitution with a methyl group in position R₂; compound **5p** was found to exhibit a single-digit micromolar inhibitory activity (IC₅₀ = 3.06 μM). The same outcome was observed for **5k** (IC₅₀ = 11.17 μM), an analog of compound **5a** (IC₅₀ = 29.18 μM). Removing the hydroxyl group resulted in decreased potency (**5k** vs. **5j**), suggesting that the hydroxyl group is a net contributor to the *in vitro* potency of the molecule. In addition, it could be noticed that the 2-OH (**5k**) on the phenyl group (R₃) presented a more potent inhibitory effect than the 3-OH (**5l**) and 4-OH (**5m**) substitution. Also, the substitution of the phenyl ring with a chloro group in position 5 increased the potency (**5p** vs. **5k**, **5b** vs. **5a**). These results revealed that the position of the substituent on the phenyl group (R₃) has a remarkable effect on the inhibitory activity. In particular, compound **5n** showed the best inhibitory effect against MGC-803 with an IC₅₀ value of 0.93 μM (10-fold more potent than **3-AP**).

Because compound **5n** exhibits potent proliferative inhibitory activity *in vitro*, we further characterized the selectivity of this compound against GES-1 (normal human gastric epithelial cell line). As can be seen in Table 2, we found that compound **5n** did not show a significant inhibitory effect on GES-1, compared to the positive control, **3-AP**. Our findings indicate that compound **5n** has good selectivity between cancer and normal cells.

Among those compounds, we chose compound **5n**, exhibiting the most potent activity against MGC-803 with an IC₅₀ value of 0.93 ± 0.02 μmol L⁻¹, to further investigate its inhibitory effect on MGC-803. As shown in Fig. 2A, the

Scheme 1 Reagents and conditions: a: (i) methanol, triethylamine, rt, 1 h; (ii) hydrazine hydrate 80%, reflux, 3 h; b: methanol, appropriate aldehyde, reflux, 4 h.

Table 1 Inhibitory results of the novel thiosemicarbazone derivatives against three cancer cell lines

				IC ₅₀ ^a (μM)		
				MGC-803	SMMC-7721	MCF-7
Comp	R ₁	R ₂	R ₃			
5a		H		29.18 ± 1.46	37.28 ± 1.57	>64
5b		H		16.31 ± 1.21	35.32 ± 1.54	>64
5c		H		20.38 ± 1.46	32.62 ± 1.51	>64
5d		H		56.05 ± 1.74	38.26 ± 1.58	>64
5e		H		>64	>64	>64
5f		H		32.59 ± 1.51	>64	>64
5g		H		>64	44.88 ± 1.65	>64
5h		H		10.17 ± 1.00	27.34 ± 1.43	41.92 ± 1.62
5i		H		2.42 ± 0.38	34.06 ± 1.53	12.38 ± 1.09
5j		CH ₃		32.61 ± 1.10	>64	44.64 ± 1.65
5k		CH ₃		11.17 ± 0.85	>64	49.23 ± 1.69
5l		CH ₃		>64	>64	>64
5m		CH ₃		>64	>64	>64
5n		CH ₃		0.93 ± 0.02	19.18 ± 1.28	9.99 ± 1.00
5o		CH ₃		>64	>64	>64
5p		CH ₃		3.06 ± 0.48	>64	29.15 ± 1.46
5q		CH ₃		58.37 ± 1.76	>64	>64
3-AP	—	—	—	9.68 ± 0.93	42.81 ± 1.63	18.85 ± 1.27

^a Inhibitory activity was assayed by exposure to substances for 72 h and expressed as the concentration required to inhibit tumor cell proliferation by 50% (IC₅₀). Data are presented as mean ± SD of three independent experiments.

antiproliferative activity of compound 5n against MGC-803 is presented in a dose-dependent and time-dependent manner with IC₅₀ values of >64, 9.22 ± 0.96, and 0.93 ± 0.02 μmol L⁻¹

at 24 h, 48 h, and 72 h, respectively. The colony formation assay shown in Fig. 2B also demonstrated that compound 5n could inhibit the proliferation of MGC-803.

Table 2 Inhibitory results of compound **5n** and **3-AP** against the normal gastric epithelial cell line GES-1 and the gastric cancer cell line MGC-803

Comp	IC ₅₀ ^a (μM)	
	GES-1	MGC-803
5n	27.93 ± 1.254	0.93 ± 0.02
3-AP	5.40 ± 0.73	9.68 ± 0.93

^a Inhibitory activity was assayed by exposure for 72 h to substances and expressed as the concentration required to inhibit normal and tumor cell proliferation by 50% (IC₅₀). Data are presented as mean ± SD of three independent experiments.

To better understand the anti-proliferative activity of compound **5n** against MGC-803, cell-cycle analysis was performed. After treatment with compound **5n** for 48 h, it was observed that the percentage of cells in the S phase was 28.4%, 32.82%, 46.07%, and 51.85% at different concentrations of 0, 0.1, 0.25, and 0.5 μmol L⁻¹, respectively, which demonstrated that compound **5n** caused an obvious S-phase arrest pattern against MGC-803 in a dose-dependent manner.

Anti-migration and anti-invasion assays. As described in the introduction, the migration and invasion ability of tumor cells is an intractable problem in cancer therapy, while EMT is tightly associated with the migration and invasion of tumor cells. Excitingly, compound **5n** could potentially inhibit

this transition. As shown in Fig. 3, wound healing, transwell and matrigel-coated transwell assays all demonstrated that compound **5n** could inhibit the migration and invasion ability of MGC-803 in a dose-dependent manner.

We also examined the expression of some typical proteins of the EMT process. The western blotting assay showed that compound **5n** could up-regulate the expression of the epithelial cell biomarker, E-cadherin, while the mesenchymal cell biomarker, N-cadherin, is down-regulated. These data indicated that compound **5n** may impair the migration and invasion ability of MGC-803 cells through inhibiting the EMT process.

Cell apoptosis analysis. Inducing the apoptosis of tumor cells is considered a major way to defeat cancer. Due to its potent activity against MGC-803 cells, compound **5n** was chosen to evaluate its influence on the apoptosis of MGC-803 cells. We observed the morphology of MGC-803 under the treatment of compound **5n** at different concentrations (0, 0.1, 0.25, and 0.5 μmol L⁻¹) for 48 h, and the changes in the morphology were observed by fluorescence microscopy using Hoechst 33258 staining. As shown in Fig. 4A, with increasing compound concentration, the typical apoptotic markers, including cell rounding, chromatin shrinkage and apoptotic bodies, become more and more frequently compared with the control. Meanwhile, the data obtained using

Fig. 2 Effects of compound **5n** on the proliferation of the human gastric cancer cell line MGC-803. (A) MGC-803 were treated with compound **5n** at different concentrations for 24, 48, and 72 h, respectively, then the MTT assay was used to evaluate its effect on cell viability; (B) the colony formation after treatment with compound **5n** at different concentrations for 7 days; (C) effect of compound **5n** on the cell cycle distribution of MGC-803. Cells were treated with different concentrations of compound **5n** for 48 h. Then, the cells were fixed and stained with PI to analyze their DNA content by flow cytometry. The experiments were performed three times, and a representative experiment is shown.

Fig. 3 Compound **5n** blocked the migration and invasion of MGC-803. (A) Anti-migration analysis performed using the wound healing assay after treatment of MGC-803 cells with compound **5n** for 48 h; (B) anti-migration and anti-invasion analyses performed using transwell and matrigel-coated transwell assays, respectively, after treatment of MGC-803 cells with compound **5n** for 48 h; (C) expression of E-cadherin and N-cadherin in MGC-803 cells after treatment with compound **5n** for 48 h. $**P < 0.01$ was considered statistically highly significant. Data are presented as mean $\pm$ SD. All experiments were carried out at least three times.

Annexin V-FITC/PI double staining implied that after 48 h of treatment with compound **5n**, the total percentage of early apoptosis and late apoptosis increased up to 10.9%, 16.4%, and 32.3% compared to the control (3.7%), which

was presented in a concentration-dependent manner (Fig. 4B).

To further clarify the mechanism of the apoptosis induced by compound **5n**, we investigated the key proteins in the

Fig. 4 Compound **5n** induced apoptosis in MGC-803. (A) Apoptosis analysis using Hoechst-33258 staining after treatment of MGC-803 cells with compound **5n** for 48 h; (B) quantitative analysis of apoptotic cells using Annexin V-FITC/PI double staining and flow-cytometry calculation; quadrant Q2 represents live cells, quadrant Q3 is for early/primary apoptotic cells, and quadrant Q4 is for late/secondary apoptotic cells, while quadrant Q1 represents cells damaged during the procedure; (C) expression of Bax and Bcl-2 in MGC-803 cells after treatment with compound **5n** for 48 h. $**P < 0.01$ was considered statistically highly significant. Data are presented as mean $\pm$ SD. All experiments were carried out at least three times.

mitochondria-related apoptotic pathway. As shown in Fig. 4C, the pro-apoptotic protein, Bax, was up-regulated after the treatment with compound **5n**, while the anti-apoptotic protein, Bcl-2, was down-regulated, which were all presented in a concentration-dependent manner. These findings indicated that compound **5n** may be involved in mitochondria-related apoptosis.

Conclusions

In summary, we have synthesized and identified a series of thiosemicarbazone-based analogues as potent and selective antiproliferative agents to modulate cancer cell growth, migration, and invasion. The structure-activity relationship

study showed that compound **5n** had the best inhibitory activity with an IC_{50} value of $0.93 \mu\text{M}$ (about 10-fold more potent than 3-AP) against MGC-803 without significant cytotoxicity against gastric epithelial immortalized GES-1 cells. Further mechanism studies revealed that compound **5n** regulates the proliferation activity of MGC-803 cells by inducing apoptosis, arresting the cell cycle at the S phase, and inhibiting the EMT. Further SAR and mechanistic studies on the selectivity toward MGC-803 cells are ongoing in our laboratories and will be reported in due course.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Project No. 81430085 and No. 21372206 for H.-M. L. and No. 81703328 for L.-Y. M.); the National Key Research Program of Proteins (No. 2016YFA0501800); the Key Research Program of Henan Province (No. 1611003110100 for H.-M. L.).

Notes and references

- 1 Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski and D. R. Richardson, Chelators at the cancer coalface: desferrioxamine to Triapine and beyond, *Clin. Cancer Res.*, 2006, **12**, 6876–6883.
- 2 J. L. Buss, F. M. Torti and S. V. Torti, The role of iron chelation in cancer therapy, *Curr. Med. Chem.*, 2003, **10**, 1021–1034.
- 3 T. B. Chaston, D. B. Lovejoy, R. N. Watts and D. R. Richardson, Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311, *Clin. Cancer Res.*, 2003, **9**, 402–414.
- 4 Z. Kovacevic, D. S. Kalinowski, D. B. Lovejoy, Y. Yu, Y. Suryo Rahmanto, P. C. Sharpe, P. V. Bernhardt and D. R. Richardson, The medicinal chemistry of novel iron chelators for the treatment of cancer, *Curr. Top. Med. Chem.*, 2011, **11**, 483–499.
- 5 Y. Yu, E. Gutierrez, Z. Kovacevic, F. Saletta, P. Obeidy, Y. Suryo Rahmanto and D. R. Richardson, Iron chelators for the treatment of cancer, *Curr. Med. Chem.*, 2012, **19**, 2689–2702.
- 6 F. Tisato, C. Marzano, M. Porchia, M. Pellei and C. Santini, Copper in diseases and treatments, and copper-based anti-cancer strategies, *Med. Res. Rev.*, 2010, **30**, 708–749.
- 7 D. B. Lovejoy, P. J. Jansson, U. T. Brunk, J. Wong, P. Ponka and D. R. Richardson, Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes, *Cancer Res.*, 2011, **71**, 5871–5880.
- 8 B. M. Zeglis, V. Divilov and J. S. Lewis, Role of metalation in the topoisomerase II α inhibition and antiproliferation activity of a series of α -heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes, *J. Med. Chem.*, 2011, **54**, 2391–2398.
- 9 D. Palanimuthu, S. V. Shinde, K. Somasundaram and A. G. Samuelson, In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes, *J. Med. Chem.*, 2013, **56**, 722–734.
- 10 A. R. Cowley, J. Davis, J. R. Dilworth, P. S. Donnelly, R. Dobson, A. Nightingale, J. M. Peach, B. Shore, D. Kerr and L. Seymour, Fluorescence studies of the intra-cellular distribution of zinc bis(thiosemicarbazone) complexes in human cancer cells, *Chem. Commun.*, 2005, 845–847.
- 11 S. I. Pascu, P. A. Waghorn, T. D. Conry, B. Lin, H. M. Betts, J. R. Dilworth, R. B. Sim, G. C. Churchill, F. I. Aigbirhio and J. E. Warren, Cellular confocal fluorescence studies and cytotoxic activity of new Zn(II) bis(thiosemicarbazone) complexes, *Dalton Trans.*, 2008, 2107–2110.
- 12 C. R. Kowol, R. Trondl, V. B. Arion, M. A. Jakupiec, I. Lichtscheidl and B. K. Keppler, Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex, *Dalton Trans.*, 2010, **39**, 704–706.
- 13 A. E. Stacy, D. Palanimuthu, P. V. Bernhardt, D. S. Kalinowski, P. J. Jansson and D. R. Richardson, Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity, *J. Med. Chem.*, 2016, **59**, 4965–4984.
- 14 Y. Yu, D. S. Kalinowski, Z. Kovacevic, A. R. Siafakas, P. J. Jansson, C. Stefani, D. B. Lovejoy, P. C. Sharpe, P. V. Bernhardt and D. R. Richardson, Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors, *J. Med. Chem.*, 2009, **52**, 5271–5294.
- 15 R. A. Finch, M. Liu, S. P. Grill, W. C. Rose, R. Loomis, K. M. Vasquez, Y. Cheng and A. C. Sartorelli, Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity, *Biochem. Pharmacol.*, 2000, **59**, 983–991.
- 16 J. Yuan, D. B. Lovejoy and D. R. Richardson, Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment, *Blood*, 2004, **104**, 1450–1458.
- 17 D. R. Richardson, P. C. Sharpe, D. B. Lovejoy, D. Senaratne, D. S. Kalinowski, M. Islam and P. V. Bernhardt, Dipyriddy thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity, *J. Med. Chem.*, 2006, **49**, 6510–6521.
- 18 C. R. Kowol, R. Berger, R. Eichinger, A. Roller, M. A. Jakupiec, P. P. Schmidt, V. B. Arion and B. K. Keppler, Gallium(III) and iron(III) complexes of α -N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase, *J. Med. Chem.*, 2007, **50**, 1254–1265.
- 19 C. R. Kowol, R. Eichinger, M. A. Jakupiec, M. Galanski, V. B. Arion and B. K. Keppler, Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones, *J. Inorg. Biochem.*, 2007, **101**, 1946–1957.
- 20 D. R. Richardson, D. S. Kalinowski, V. Richardson, P. C. Sharpe, D. B. Lovejoy, M. Islam and P. V. Bernhardt, 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity, *J. Med. Chem.*, 2009, **52**, 1459–1470.
- 21 D. B. Lovejoy, D. M. Sharp, N. Seebacher, P. Obeidy, T. Prichard, C. Stefani, M. T. Basha, P. C. Sharpe, P. J. Jansson,

- D. S. Kalinowski, P. V. Bernhardt and D. R. Richardson, Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo, *J. Med. Chem.*, 2012, **55**, 7230–7244.
- 22 D. B. Lovejoy and D. R. Richardson, Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells, *Blood*, 2002, **100**, 666–676.
- 23 Z. Kovacevic, S. Chikhani, D. B. Lovejoy and D. R. Richardson, Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer, *Mol. Pharmacol.*, 2011, **80**, 598–609.
- 24 Y. Yu, Y. Suryo Rahmanto and D. R. Richardson, Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy, *Br. J. Pharmacol.*, 2012, **165**, 148–166.
- 25 M. J. Mackenzie, D. Saltman, H. Hirte, J. Low, C. Johnson, G. Pond and M. J. Moore, A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma, A trial of the Princess Margaret hospital Phase II consortium, *Invest. New Drugs*, 2007, **25**, 553–558.
- 26 J. E. Karp, F. J. Giles, I. Gojo, L. Morris, J. Greer, B. Johnson, M. Thein, M. Sznol and J. Low, A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders, *Leuk. Res.*, 2008, **32**, 71–77.
- 27 B. Ma, B. C. Goh, E. H. Tan, K. C. Lam, R. Soo, S. S. Leong, L. Z. Wang, F. Mo, A. T. Chan, B. Zee and T. Mok, A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells, *Invest. New Drugs*, 2008, **26**, 169–173.
- 28 Y. Yen, K. Margolin, J. Doroshow, M. Fishman, B. Johnson, C. Clairmont, D. Sullivan and M. Sznol, A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer, *Cancer Chemother. Pharmacol.*, 2004, **54**, 331–342.
- 29 J. J. Knox, S. J. Hotte, C. Kollmannsberger, E. Winquist, B. Fisher and E. A. Eisenhauer, Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161), *Invest. New Drugs*, 2007, **25**, 471–477.
- 30 A. M. Traynor, J. W. Lee, G. K. Bayer, J. M. Tate, S. P. Thomas, M. Mazurczak, D. L. Graham, J. M. Kolesar and J. H. Schiller, A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503, *Invest. New Drugs*, 2010, **28**, 91–97.
- 31 S. C. Chu, C. C. Yu, L. S. Hsu, K. S. Chen, M. Y. Su and P. N. Chen, Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells, *Mol. Pharmacol.*, 2014, **86**, 609–623.
- 32 S. Lamouille, J. Xu and R. Derynck, Molecular mechanisms of epithelial-mesenchymal transition, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 178–196.
- 33 J. P. Thiery and J. P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions, *Nat. Rev. Mol. Cell Biol.*, 2006, **7**, 131–142.
- 34 J. P. Thiery, H. Acloque, R. Y. Huang and M. A. Nieto, Epithelial-mesenchymal transitions in development and disease, *Cell*, 2009, **139**, 871–890.
- 35 G. Berx, E. Raspe, G. Christofori, J. P. Thiery and J. P. Sleeman, Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer, *Clin. Exp. Metastasis*, 2007, **24**, 587–597.
- 36 M. Jechlinger, S. Grunert, I. H. Tamir, E. Janda, S. Ludemann, T. Waerner, P. Seither, A. Weith, H. Beug and N. Kraut, Expression profiling of epithelial plasticity in tumor progression, *Oncogene*, 2003, **22**, 7155–7169.
- 37 L. Y. Ma, Y. C. Zheng, S. Q. Wang, B. Wang, Z. R. Wang, L. P. Pang, M. Zhang, J. W. Wang, L. Ding, J. Li, C. Wang, B. Hu, Y. Liu, X. D. Zhang, J. J. Wang, Z. J. Wang, W. Zhao and H. M. Liu, Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents, *J. Med. Chem.*, 2015, **58**, 1705–1716.